Collision of herbal medicine and nanotechnology: a bibliometric analysis of herbal nanoparticles from 2004 to 2023

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background

Herbal nanoparticles are made from natural herbs/medicinal plants, their extracts, or a combination with other nanoparticle carriers. Compared to traditional herbs, herbal nanoparticles lead to improved bioavailability, enhanced stability, and reduced toxicity. Previous research indicates that herbal medicine nanomaterials are rapidly advancing and making significant progress; however, bibliometric analysis and knowledge mapping for herbal nanoparticles are currently lacking. We performed a bibliometric analysis by retrieving publications related to herbal nanoparticles from the Web of Science Core Collection (WoSCC) database spanning from 2004 to 2023. Data processing was performed using the R package Bibliometrix, VOSviewers, and CiteSpace.

Results

In total, 1876 articles related to herbal nanoparticles were identified, originating from various countries, with China being the primary contributing country. The number of publications in this field increases annually. Beijing University of Chinese Medicine, Shanghai University of Traditional Chinese Medicine, and Saveetha University in India are prominent research institutions in this domain. The Journal “International Journal of Nanomedicine” has the highest number of publications. The number of authors of these publications reached 8234, with Yan Zhao, Yue Zhang, and Huihua Qu being the most prolific authors and Yan Zhao being the most frequently cited author. “Traditional Chinese medicine,” “drug delivery,” and “green synthesis” are the main research focal points. Themes such as “green synthesis,” “curcumin,” “wound healing,” “drug delivery,” and “carbon dots” may represent emerging research areas.

Conclusions

Our study findings assist in identifying the latest research frontiers and hot topics, providing valuable references for scholars investigating the role of nanotechnology in herbal medicine.

Graphical Abstract

Supplementary Information

The online version contains supplementary material available at 10.1186/s12951-024-02426-3.

Related collections

Most cited references 186

Record: found
Abstract: not found
Article: not found

bibliometrix : An R-tool for comprehensive science mapping analysis

Corrado Cuccurullo, Massimo Aria (2017)

0 comments Cited 1660 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Daniel Von Hoff, Thomas Ervin, Francis Arena … (2013)

In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted a phase 3 study of the efficacy and safety of the combination versus gemcitabine monotherapy in patients with metastatic pancreatic cancer. We randomly assigned patients with a Karnofsky performance-status score of 70 or more (on a scale from 0 to 100, with higher scores indicating better performance status) to nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks or gemcitabine monotherapy (1000 mg per square meter) weekly for 7 of 8 weeks (cycle 1) and then on days 1, 8, and 15 every 4 weeks (cycle 2 and subsequent cycles). Patients received the study treatment until disease progression. The primary end point was overall survival; secondary end points were progression-free survival and overall response rate. A total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430). The median overall survival was 8.5 months in the nab-paclitaxel-gemcitabine group as compared with 6.7 months in the gemcitabine group (hazard ratio for death, 0.72; 95% confidence interval [CI], 0.62 to 0.83; P<0.001). The survival rate was 35% in the nab-paclitaxel-gemcitabine group versus 22% in the gemcitabine group at 1 year, and 9% versus 4% at 2 years. The median progression-free survival was 5.5 months in the nab-paclitaxel-gemcitabine group, as compared with 3.7 months in the gemcitabine group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.58 to 0.82; P<0.001); the response rate according to independent review was 23% versus 7% in the two groups (P<0.001). The most common adverse events of grade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). Febrile neutropenia occurred in 3% versus 1% of the patients in the two groups. In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3 or higher improved to grade 1 or lower in a median of 29 days. In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.).

0 comments Cited 1181 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

An index to quantify an individual's scientific research output.

J. E. Hirsch (2005)

I propose the index h, defined as the number of papers with citation number > or =h, as a useful index to characterize the scientific output of a researcher.

0 comments Cited 1126 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Liang Peng: pengliang8028@163.com

Zhen Wang: zhenwangdzm@126.com

Yaoxian Wang: wyx3203@sina.com

Journal

Journal ID (nlm-ta): J Nanobiotechnology

Journal ID (iso-abbrev): J Nanobiotechnology

Title: Journal of Nanobiotechnology

Publisher: BioMed Central (London )

ISSN (Electronic): 1477-3155

Publication date (Electronic): 1 April 2024

Publication date PMC-release: 1 April 2024

Publication date Collection: 2024

Volume: 22

Electronic Location Identifier: 140

Affiliations

[1 ]China-Japan Friendship Hospital, ( https://ror.org/037cjxp13) Beijing, China

[2 ]GRID grid.415954.8, ISNI 0000 0004 1771 3349, Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases, Institute of Medical Science, , China-Japan Friendship Hospital, ; Beijing, China

[3 ]GRID grid.24696.3f, ISNI 0000 0004 0369 153X, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, ; Beijing, China

[4 ]Dongzhimen Hospital, Beijing University of Chinese Medicine, ( https://ror.org/05damtm70) Beijing, China

[5 ]GRID grid.411610.3, ISNI 0000 0004 1764 2878, Beijing Friendship Hospital, Capital Medical University, ; Beijing, China

[6 ]GRID grid.256922.8, ISNI 0000 0000 9139 560X, Henan University of Chinese Medicine, ; Zhengzhou, Henan China

Article

Publisher ID: 2426

DOI: 10.1186/s12951-024-02426-3

PMC ID: 10983666

PubMed ID: 38556857

SO-VID: 3f624cb1-9938-4810-aaff-f1e66e9bb9b8

License:

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

History

Date received : 13 November 2023

Date accepted : 18 March 2024

Funding

Funded by: National Natural Science Foundation of China

Award ID: 82004272

Award ID: 82170817

Award ID: 82274460

Award ID: 82174342

Award Recipient : Huijuan Zheng Liang Peng Zhen Wang Yaoxian Wang

Funded by: Beijing Municipal Natural Science Foundation of China

Award ID: 7222160

Award Recipient : Liang Peng

Funded by: National High Level Hospital Clinical Research Funding

Award ID: 2023-NHLHCRF-DJZD-01

Award Recipient : Liang Peng

Funded by: Beijing Research Ward Construction Clinical Research

Award ID: 2022-YJXBF-04-02

Award Recipient : Liang Peng

Custom metadata

ScienceOpen disciplines: Biotechnology

Keywords: herbal nanoparticles,herbal medicine,traditional chinese medicine,nanoparticles,bibliometric analysis,vosviewer,citespace

Data availability:

ScienceOpen disciplines: Biotechnology

Keywords: herbal nanoparticles, herbal medicine, traditional chinese medicine, nanoparticles, bibliometric analysis, vosviewer, citespace

Collision of herbal medicine and nanotechnology: a bibliometric analysis of herbal nanoparticles from 2004 to 2023

Read this article at

Abstract

Background

Results

Conclusions

Graphical Abstract

Supplementary Information

Related collections

Genome Engineering using CRISPR

Most cited references 186

bibliometrix : An R-tool for comprehensive science mapping analysis

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

An index to quantify an individual's scientific research output.

Author and article information

Contributors

Journal

Affiliations

Article

History

Funding

Categories

Custom metadata

Comments

Comment on this article

Similar content 112

Cited by 1

Most referenced authors 2,526